These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23469943)

  • 1. Platelet activation and inhibition in sickle cell disease (pains) study.
    Frelinger AL; Jakubowski JA; Brooks JK; Carmichael SL; Berny-Lang MA; Barnard MR; Heeney MM; Michelson AD
    Platelets; 2014; 25(1):27-35. PubMed ID: 23469943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
    Jakubowski JA; Zhou C; Winters KJ; Lachno DR; Howard J; Payne CD; Mant T; Jurcevic S; Frelinger AL
    Platelets; 2015; 26(5):474-9. PubMed ID: 25140584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.
    Ohno K; Tanaka H; Samata N; Jakubowski JA; Tomizawa A; Mizuno M; Sugidachi A
    Thromb Res; 2014 Oct; 134(4):889-94. PubMed ID: 25130912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.
    Jakubowski JA; Zhou C; Jurcevic S; Winters KJ; Lachno DR; Frelinger AL; Gupta N; Howard J; Payne CD; Mant TG
    Thromb Res; 2014 Feb; 133(2):190-5. PubMed ID: 24368019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.
    Jakubowski JA; Zhou C; Small DS; Winters KJ; Lachno DR; Frelinger AL; Howard J; Mant TG; Jurcevic S; Payne CD
    Br J Clin Pharmacol; 2013 Jun; 75(6):1433-44. PubMed ID: 23171128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
    Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S
    Eur J Clin Invest; 2013 Jul; 43(7):689-97. PubMed ID: 23611368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
    Jakubowski JA; Zhou C; Egan B; Wells M; Kotob-Yahfoufi M; Sugidachi A; Dahlen JR
    Platelets; 2011; 22(8):619-25. PubMed ID: 21639823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
    Frelinger AL; Jakubowski JA; Li Y; Barnard MR; Fox ML; Linden MD; Sugidachi A; Winters KJ; Furman MI; Michelson AD
    Thromb Haemost; 2007 Jul; 98(1):192-200. PubMed ID: 17598013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
    Khanna V; Armstrong PC; Warner TD; Curzen N
    Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
    Badr Eslam R; Lang IM; Kaider A; Panzer S
    Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
    Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
    J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
    Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.
    Jakubowski JA; Hoppe CC; Zhou C; Smith BE; Brown PB; Heath LE; Inusa B; Rees DC; Small DS; Gupta N; Yao S; Heeney M; Kanter J
    Thromb Haemost; 2017 Feb; 117(3):580-588. PubMed ID: 27929203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
    Braun OO; Johnell M; Varenhorst C; James S; Brandt JT; Jakubowski JA; Winters KJ; Wallentin L; Erlinge D; Siegbahn A
    Thromb Haemost; 2008 Oct; 100(4):626-33. PubMed ID: 18841285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the INNOVANCE PFA P2Y test cartridge: sensitivity to P2Y(12) blockade and influence of anticoagulant.
    Edwards A; Jakubowski JA; Rechner AR; Sugidachi A; Harrison P
    Platelets; 2012; 23(2):106-15. PubMed ID: 21848368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
    Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
    Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.